1-5 of 5
Ted Shih
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Emma Searle, Francesco Forconi, Kim Linton, Alexey Danilov, Pam McKay, David Lewis, Dima El-Sharkawi, Mary Gleeson, John Riches, Sarah G. Injac, Ted Shih, Srinand Nandakumar, May Tan, Ganesh Cherala, Erin Meredith, Graham P. Collins
Journal: Blood
Blood (2023) 142 (Supplement 1): 4473.
https://doi.org/10.1182/blood-2023-179508
Published: 2023
Journal Articles

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Murali Janakiram, MD, Ravi Vij, MBBS, David S. Siegel, MD PhD, Ted Shih, PharmD, Sara Weymer, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3.
https://doi.org/10.1182/blood-2020-137715
Published: 2020
Journal Articles

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Clinical Trials & Observations
Mrinal M. Patnaik, David A. Sallman, Abhishek A. Mangaonkar, Rachel Heuer, Jeffery Hirvela, Darci Zblewski, Aref Al-Kali, Moritz Binder, Maria E. Balasis, Hannah Newman, Christopher Letson, Traci L. Kruer, Naseema Gangat, Rami S. Komrokji, Ayalew Tefferi, Adrian Lo, Ted Shih, Cameron Durrant, Alan F. List, Eric Padron
Journal: Blood
Blood (2020) 136 (7): 909–913.
https://doi.org/10.1182/blood.2019004352
Published: 2020
Includes: Supplemental data
Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1594.
https://doi.org/10.1182/blood-2019-125485
Published: 2019
Journal Articles

Monitoring of Calr Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses

Gabriela M. Baerlocher, MD, Monika Haubitz, PhD, Oliver G. Ottmann, MD, Olatoyosi Odenike, MBBS, Alexander Roeth, MD, Michael A McDevitt, MD PhD, Ted Shih, Bart Burington, Dianne Morfeld, Neeru Batra, BS, David Snyder, MD, Elisabeth Oppliger Leibundgut, PharmD
Journal: Blood
Blood (2014) 124 (21): 408.
https://doi.org/10.1182/blood.V124.21.408.408
Published: 2014